Hubei Hongyuan Pharmaceutical Technology Co., Ltd. (SHE:301246)

Market Cap	10.00B +83.7%
Revenue (ttm)	1.94B +9.5%
Net Income	119.05M +131.3%
EPS	0.30 +132.3%
Shares Out	396.81M
PE Ratio	84.03
Forward PE	n/a
Dividend	0.03 (0.12%)
Ex-Dividend Date	Jun 25, 2025

Volume	17,202,210
Average Volume	22,058,327
Open	25.53
Previous Close	25.53
Day's Range	25.05 - 25.80
52-Week Range	12.64 - 28.79
Beta	0.47
RSI	61.96
Earnings Date	Apr 29, 2026

About SHE:301246

Hubei Hongyuan Pharmaceutical Technology Co., Ltd., together with its subsidiaries, produces and sells pharmaceutical products in China and internationally. The company offers active pharmaceutical ingredients, such as metronidazole, benzoyl metronidazole, dimetrizole, and acyclovir; pharmaceutical intermediates, including imidazole, glyoxylic acid, 2-methyl imidazole, 2-methyl-5-nitroimidazole, sulfate, guanine, diacetyl guanine, and diacetylacyclovir; organic chemical raw materials comprising glyoxal, and oxalic acid; and new energy materials...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2002
• Employees: 2,169
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 301246

Financial Performance

In 2025, SHE:301246's revenue was 1.94 billion, an increase of 9.53% compared to the previous year's 1.77 billion. Earnings were 119.05 million, an increase of 131.33%.